Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

19-06-2018 | Renal cell carcinoma | ASCO 2018 | News

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

31-05-2018 | Genitourinary cancers | Themed collection | Collection

Best of JCO™ 2018: Genitourinary Cancer Edition

The content compiled here represents some of the most-accessed original research from recently published Journal of Clinical Oncology articles across a range of topics including prostate and bladder cancer. 

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

Latest from across the site

22-06-2018 | Non-small cell lung cancer | ASCO 2018 | Article

News in brief

Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC

The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer patients with heavily pretreated, advanced ALK-positive disease.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA

22-06-2018 | Early stage breast cancer | ASCO 2018 | News

Mixed results for denosumab for the prevention of breast cancer recurrence

Two opposing sets of phase III results regarding the effect of denosumab on the recurrence of hormone receptor-positive nonmetastatic breast cancer have been presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA

21-06-2018 | Rhabdomyosarcoma | ASCO 2018 | News

News in brief

Maintenance therapy boosts high-risk pediatric rhabdomyosarcoma survival

A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.

20-06-2018 | Non-small cell lung cancer | ASCO 2018 | News

Atezolizumab boosts survival in metastatic nonsquamous NSCLC

Adding atezolizumab to bevacizumab plus chemotherapy significantly delays disease progression and death among chemotherapy-naïve patients with metastatic nonsquamous non-small-cell lung cancer, phase III study data show.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA, N Engl J Med 2018; 378: 2288–2301

19-06-2018 | Renal cell carcinoma | ASCO 2018 | News

News in brief

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.

19-06-2018 | Renal cell carcinoma | ASCO 2018 | News

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits